Skip to main content
SpringerLink
Log in

Drug design

Designing drugs with reversible activity

  • News & Views
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

A strategy for creating drugs that can be quickly neutralized is demonstrated for anticoagulants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Schematic representation of DNA and PNA derivatives and their pharmaceutical applications.

References

  1. Dockerill, M. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02209-z (2024).

    Article  Google Scholar 

  2. Hirsh, J., Anand, S. S., Halperin, J. L. & Fuster, V. Circulation 103, 2994–3018 (2001).

    Article  CAS  PubMed  Google Scholar 

  3. Brenner, S. & Lerner, R. A. Proc. Natl Acad. Sci. USA 89, 5381–5383 (1992).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Melkko, S., Scheuermann, J., Dumelin, C. E. & Neri, D. Nat. Biotechnol. 22, 568–574 (2004).

    Article  CAS  PubMed  Google Scholar 

  5. Mannocci, L. et al. Proc. Natl Acad. Sci. USA 105, 17670–17675 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gartner, Z. J. et al. Science 305, 1601–1605 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Clark, M. A. et al. Nat. Chem. Biol. 5, 647–654 (2009).

    Article  CAS  PubMed  Google Scholar 

  8. Barluenga, S. & Winssinger, N. Acc. Chem. Res. 48, 1319–1331 (2015).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Philogen SpA, Siena, Italy

    Dario Neri

  2. ETH Zürich, Zurich, Switzerland

    Dario Neri

Authors
  1. Dario Neri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dario Neri.

Ethics declarations

Competing interests

D.N. is co-founder, CEO and shareholder of Philogen, a biotech company that works (among other things) in the field of DNA-encoded chemical libraries.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neri, D. Designing drugs with reversible activity. Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02242-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41587-024-02242-y

  • Springer Nature America, Inc.

Search

Navigation